An open-lebel trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients

Solaro, Claudio; Lunardi, G.; Capello, Elisabetta; Inglese, Matilde; Uccelli, Michele Messmer; Uccelli, Antonio; Mancardi, Gianluigi

doi:10.1212/wnl.51.2.609

Cited by 110 publications

(53 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One was an open-label report of the effect of gabapentin on paroxysmal symptoms in MS 48 and another a report of two cases. 49 The other two were randomised, placebocontrolled, crossover studies 50,51 of its effect on spasticity in MS.…”

Section: Quantity Of Research Availablementioning

confidence: 99%

“…Two open-label, uncontrolled studies suggest that gabapentin is effective in treating a wide variety of pain syndromes in MS. 48,114 One reports its use, in doses up to 1.2 g daily, in 21 MS patients with paroxysmal symptoms. 48 Of these, six had trigeminal neuralgia (in whom treatment with carbamazepine or phenytoin had been tried and abandoned), and 11 had painful tonic spasms.…”

Section: Gabapentinmentioning

confidence: 99%

“…48 Of these, six had trigeminal neuralgia (in whom treatment with carbamazepine or phenytoin had been tried and abandoned), and 11 had painful tonic spasms. In all but one patient with painful spasms who dropped out, there was significant relief of symptoms.…”

Section: Gabapentinmentioning

confidence: 99%

See 2 more Smart Citations

Treatments for spasticity and pain in multiple sclerosis: a systematic review

Beard

Hunn²,

Wight³

2003

Health Technol Assess

237

131

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents, York Publishing Services by:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS and public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please contact York Publishing Services at the address above. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to York Publishing Distribution and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.ncchta.org/htacd.htm). Or contact York Publishing Services (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTATreatments for spasticity and pain in multiple sclerosis: a systematic review NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme and funded as project number 99/05/03. Technology assessment reports are completed in a limited time to inform decisions in key areas by bringing together evidence on the use of the technology concerned.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. HTA Programme Director:Professor Kent Woods Series Editors:Professor Andrew Stevens, Dr Ken Stein, Professor John Gabbay, Dr Ruairidh Milne, Dr Chris Hyde and Dr Rob Riemsma Managing Editors:Sally Bailey and ...

show abstract

Section: Quantity Of Research Availablementioning

confidence: 99%

Section: Gabapentinmentioning

confidence: 99%

See 1 more Smart Citation

Treatments for spasticity and pain in multiple sclerosis: a systematic review

Beard

Hunn²,

Wight³

2003

Health Technol Assess

237

131

View full text Add to dashboard Cite

show abstract

“…Over the past few years, it has received increasing attention as a drug potentially useful for treatment of neuropathic pain. Anecdotal and open-label series reports have discussed its efficacy in a wide variety of painful conditions, including complex regional pain syndromes, trigeminal neuralgia, postherpetic neuralgia, and neuropathic pain of the head and neck (40)(41)(42)(43)(44)(45). It was also found to be effective in reducing tactile allodynia, mechano hyperalgesia, and thermal hyperalgesia in a variety of animal models of neuropathic pain, including the chronic constriction injury model (46), the formalin and carageenan foodpad tests, the streptozotocin model, and a model of postoperative pain (47)(48)(49)(50).…”

Section: Gabapentin and The Treatment Of Painmentioning

confidence: 99%

Postherpetic Neuralgia: Role of Gabapentin and Other Treatment Modalities

Beydoun

1999

Epilepsia

View full text Add to dashboard Cite

Summary: Postherpetic neuralgia (PHN) is a chronic and painful condition that may occur after a herpes zoster infection. The frequency of PHN after untreated zoster varies widely. Age is the most important risk factor for development of PHN. The condition occurs in an estimated 50% of patients older than 50 years. The pain of PHN can be severe and debilitating and is frequently associated with allodynia. Although in most patients pain remits within the first year, it may persist for a lifetime. Tricyclic antidepressants (TCAs), topical agents, opioids, and gabapentin, a structural y-amino butyric acid (GABA) analogue, are the only agents that have demonstrated efficacy in randomized clinical trials for treatment of both the shooting and the burning form of pain associated with PHN. TCAs are among the most commonly used classes of agents for treating PHN and are effective in a significant proportion of patients. However, various adverse events can limit treatment. These side effects tend to be more acute in the elderly, the population most likely to suffer from PHN. Topical agents have led to mild to moderate improvement in patients with PHN but are usually ineffective as monotherapy for this condition. Until recently, carbamazepine was the only antiepileptic drug evaluated for the treatment of PHN. Over the past few years, however, gabapentin has received increasing attention as a useful treatment for neuropathic pain. Gabapentin lacks significant drug-drug interactions and has a favorable safety profile, which makes it particularly useful for treatment of PHN. Key Words: Postherpetic neuralgia-Gabapentin-Herpes zoster. HERPES ZOSTER POSTHERPETIC NEURALGIAPHN is a chronic painful condition that sometimes occurs after a zoster infection. Although most investigators confirm persistent pain for at least 3 months after healing of the characteristic rash before making this diagnosis, others have diagnosed PHN as early as 3 to 4 weeks after healing (15)(16)(17) or not until 6 months after healing ( 18). The frequency of PHN after untreated zoster has varied widely in different series, but a metaanalysis of 14 placebo-controlled clinical trials of acyclovir for acute zoster found that 22% of placebo-treated patients went on to develop this condition (19). The most important risk factor for developing PHN is age (20), with incidence estimates of 50% for patients older than 50 years and 75% for those above 65 years (2,4,21). Women are more commonly affected than men (22), which might be a reflection of the predominance of women in the older age group.The pain of PHN can be quite severe and incapacitating and is described as lancinating, stabbing, shooting, or steady and burning, and is frequently associated with S51

show abstract

“…Other antiepileptic drugs, such as valproic acid and phenytoin have also shown success (17). Recently an open-label trial of gabapentin for the treatment of paroxysmal symptoms in 18 patients with MS has been published (18). Successful use of bromocriptine and ibuprofen has also been reported (19)(20).…”

Section: Discussionmentioning

confidence: 99%